EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Diffuse large B‐cell lymphoma

Allison Barraclough, Eliza Hawkes, Laurie H Sehn, Sonali M Smith iD

Hematological Oncology · 2024-11 · 42 (6)

DOI: 10.1002/hon.3202 ↗

At a glance

Übersichtsarbeit in Hematological Oncology, published online on 2023-07-12. Written by Allison Barraclough and 3 co-authors. Institution: Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia. Major MEDLINE topics: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols. Cited 53 times so far (Crossref); 55 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Large B‐cell lymphoma, the prototype of aggressive non‐Hodgkin lymphomas, is both the most common lymphoma and accounts for the highest global burden of lymphoma‐related deaths. For nearly 4 decades, the goal of treatment has been “cure”, first based on CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and subsequently with rituximab plus CHOP. However, there is significant clinical, pathologic, and biologic heterogeneity, and not all patients are cured. Understanding and incorporating this biologic heterogeneity into treatment decisions unfortunately is not yet standard of care. Despite this gap, we now have significant advances in frontline, relapsed, and refractory settings. The POLARIX trial shows, for the first time, improved progression‐free survival in a prospective randomized phase 3 setting. In the relapsed and refractory settings, there are now many approved agents/regimens, and several bispecific antibodies poised to join the arsenal of options. While chimeric antigen receptor T‐cell therapy is discussed in detail elsewhere, it has quickly become an excellent option in the second‐line setting and beyond. Unfortunately, special populations such as older adults continue to have poor outcomes and be underrepresented in trials, although a new generation of trials aim to address this disparity. This brief review will highlight the key issues and advances that offer improved outcomes to an increasing portion of patients.

Subjects

MeSH terms (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsHumansCyclophosphamide

Author keywords

antibody‐drug conjugatesdiffuse large B‐cell lymphomaolder adultstreatment

Substances

Cyclophosphamide

Authors and institutions

  • Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
  • University of Melbourne, Medical School, Melbourne, Victoria, Australia.
  • Olivia Newton John Cancer Research Centre, Austin Health, Melbourne, Victoria, Australia.
  • Monash University School of Public Health & Preventive Medicine, Melbourne, Victoria, Australia.
  • BC Cancer Centre for Lymphoid Cancer, The University of British Columbia, Vancouver, British Columbia, Canada.
  • The University of Chicago Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA.

ORCID profiles: Sonali M Smith

Cite

APA

Barraclough, A., Hawkes, E., Sehn, L. H., & Smith, S. M. (2024). Diffuse large B‐cell lymphoma. Hematological Oncology, 42(6). https://doi.org/10.1002/hon.3202

Vancouver

Barraclough A, Hawkes E, Sehn LH, Smith SM. Diffuse large B‐cell lymphoma. Hematological Oncology. 2024;42(6). doi:10.1002/hon.3202

BibTeX
@article{Barraclough2024,
  author = {Barraclough, Allison and Hawkes, Eliza and Sehn, Laurie H and Smith, Sonali M},
  title = {Diffuse large B‐cell lymphoma},
  journal = {Hematological Oncology},
  year = {2024},
  volume = {42},
  number = {6},
  doi = {10.1002/hon.3202}
}
Start for free →